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Introduction 
Drug particle that presents with limited aqueous solubility 
tend to exhibit poor dissolution profile. This can hamper oral drug 
absorption that has been related to issues of low and unpredictable 
bioavailability and lacking dose proportionality [1]. Hence dissolution 
enhancement for these drugs is crucial to avoid therapeutic failures. 
Key enhancement approaches include solubility improvement such as 
via salt formation and dissolution rate enhancement such as forming 
solid dispersions or self-emulsifying drug delivery system (SEDDS), 
each approach has its cons and pros despite showing enhancement 
for certain hydrophobic drugs [2-4]. Indapamide is a thiazide-like 
diuretic with antihypertensive effects. It is a weak acid and the partition 
coefficient for indapamide is higher than other diuretic agents including 
furosemide, hydrochlorothiazide and chlorthalidone [5]. It falls under 
Biopharmaceutical Classification System (BCS) Type 2 (low solubility 
and high permeability) [6]. Producing amorphous forms of Indapamide 
by spray drying [7,8], quench-cooling of the melt, cryogenic grinding 
and room temperature milling [9,10] have been shown to improve drug 
solubility against its crystalline form. And drug precipitation could be 
avoided by adding small amount of hydroxypropyl methylcellulose. 
Lipid-based systems that generate SEDDS have shown success with 
several marketed products being adopted [11]. This study aimed 
to investigate the feasibility of SEDDS as solubility and dissolution 
enhancing approach for Indapamide. In order to produce lipid-based 
systems, Labrasol with Hydrophilic-Lipophilic Balance (HLB) of 12 and 
Labrafil®M1944CS (HLB 9) have been chosen as the key components 
while CapryolTM90 (HLB 5) or Solutol®HS15 (HLB 14-16) as the 
third component. These vehicles and their mixtures have previously 
been reported to enhance drug dissolution profiles [12]. Effect of 
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Purpose: Poorly water-soluble drugs when given orally experience limited dissolution due to their low solubility in aqueous solutions. This study aimed to investigate 
the dissolution enhancement using self-emulsifying drug delivery systems (SEDDS) for Indapamide, a Biopharmaceutical Classification System Type 2 drug. 
Stability of SEDDS was also assessed. 
Methods: Drug containing lipid-based systems that could form SEDDS were prepared with vehicles including Labrafil®M1944CS and Labrasol with or without 
Capryol™90 or Solutol®HS15. The key quality attributes of SEDDS were determined in terms of size distribution and drug dissolution profiles. Other properties 
evaluated were critical micelle concentration (CMC), zeta potential and solubility profiles. 
Results: SEDDS formed negatively charged dispersions of typically 170-250nm and their CMC were <110mg/L. All SEDDS achieved rapid and significantly 
higher drug release, which were maintained over 90min when compared to unprocessed drug powder. Dissolution enhancement and size distribution profiles of 
SEDDS stored at 25 and 40ºC were preserved. Enhancement effect of SEDDS was contributed to formation of stable nano-sized dispersions, high drug solubility 
in SEDDS and low CMC that withstood dilution by dissolution medium. 
Conclusions: Lipid-based systems with Labrasol, Labrafil®M1944CS and Capryol™90 produced SEDDS that led to a significant dissolution enhancement of 
Indapamide regardless of storage conditions. 
blending these vehicles in different drug to lipid ratios to produce lipid-
based systems, which were suitable as SEDDS for Indapamide, were 
examined. Performances of SEDDS were analysed based on their size, 
charge, morphology, solubility and dissolution profiles. Furthermore, 
the critical micelle concentration (CMC) of SEDDS was determined. 
The stability profiles of SEDDS were also examined in terms of size 
distribution and dissolution profiles.
Materials and methods
Indapamide, phosphotungstic acid (PTA), osmium tetraoxide 
(OST), acetonitrile, ethanol and potassium dihydrogen orthophosphate 
were obtained from Sigma Aldrich (Dorset, UK). Labrasol, 
Labrafil®M1944CS and Capryol™90 were purchased from Gattefosse 
(Binfield, UK). Solutol®HS15 was obtained from BASF (Cheshire, UK). 
All chemicals were of analytical grade and used as obtained. 
Lipid-based vehicle systems were prepared by blending 
Labrafil®M1944CS and Labrasol with and without CaproylTM90 or 
Solutol®HS15. Indapamide was dissolved in the lipids at a specific 
drug to lipid ratio at 60°C (Table 1). The mixture was cooled to 25°C 
and then vortexed until clear liquids were obtained. For sample 
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characterisation, dissolution study using USP dissolution apparatus II 
(Caleva Ltd., Dorset, UK) was performed on unprocessed Indapamide 
powder, marketed generic tablets and SEDDS (all samples contained 
5mg of drug). Each sample was placed in 900mL water (as dissolution 
medium) at 37±1°C and stirred at 100rpm. A 10mL sample was 
withdrawn at fixed intervals for up to 90min and an equal amount of 
distilled water was replaced. Samples were analysed for drug levels by 
a high-performance liquid chromatography (HPLC) assay (Figure S1). 
Solubility study was conducted by placing an excessive amount of drug 
powder in either individual excipients or lipid-based systems. Samples 
were mixed and equilibrated for 48h at 37oC. After centrifugation, 
appropriate amount of supernatants were diluted in up to 50 ethanol 
before HPLC analysis. Lipid-based systems (same quantity used as 
dissolution test) were diluted in water forming SEDDS, then size 
distribution and zeta potential were determined using Malvern 
Zetasizer Nano ZSP (Cambridge, UK) [13] while the morphology of 
SEDDS was examined by transmission electron microscopy (TEM) 
(Hitachi H700, Japan) after negative staining by 2% PTA and positive 
staining by 2% OST [14]. Surface tension values of diluted SEDDS 
were determined by a tensiometer (Attension Sigma 700/701, Sweden) 
attached to a platinum ring from 1g/L stocks [15]. Following this, the 
critical micelle concentration (CMC) values of SEDDS were determined. 
The dissolution and size distribution profiles were also determined after 
three- and six-months of stability tests for lipid-based systems stored at 
40°C and 25°C, respectively. All experiments were repeated trice. One-
way ANOVA was conducted to examine whether there is statistically 
significant difference among the groups and Tukey HSD was selected as 
Post Hoc test. The significance level used was 0.05.
Results and Discussion
Indapamide solubility in individual excipients was found to be 
the highest in Labrasol and the lowest in Labrafil®M1944CS (Figure 
1), and the findings were consistent to earlier study [12]. The highest 
drug solubility was achieved with lipid-based system consisting of 10% 
CapyrolTM90. On the contrary, by substitution of 10% CapyrolTM90 
for 10% Solutol®HS15 with the highest HLB, drug solubility was lower 
due to a slight increase in overall hydrophilicity of the system. These 
lipid-based systems achieved HLB values ~11 and they were considered 
superior to individual vehicles except for Labrasol. They improved 
Indapamide solubility and the solubility enhancement was well 
exceeding the target drug content, which was 5mg. Moreover, solubility 
enhancement is considered significant comparing to drug solubility 
in water alone, where the reported drug solubility in water ranged 81-
109mg/L [10]. Hence, it is anticipated that drug partition would occur 
mainly into these lipid-based systems rather than water. 
The lipid-based systems were then prepared by using different drug 
to lipid ratios (1/10, 1/20, 1/30) initially and stored at 25°C. Periodically, 
the samples were examined visually. Samples were excluded if they 
phase separated. Those remaining as clear or transparent liquids were 
considered as stable and were selected for further analysis (Table 1). 
The mean sizes of SEDDS were in the range of 170-250nm (Figure 
2), indicating the formation of dispersed nanostructures. This is due 
to relatively high HLB values of these lipid-based systems and low 
free energy requirement for self-emulsification to occur [16]. SEDDS 
with 10% Solutol®HS15 (batch ID=S130), which is considered most 
hydrophilic, exhibited the smallest size (p<0.05) while SEDDS devoid 
of the third component (ID=B130) possessed the highest polydispersity 
index (PDI) with a less uniform size distribution. Hence, incorporating 
Solutol®HS15 or CapryolTM90 as co-surfactant that changed interfacial 
fluidity was found to be beneficial to self-emulsification process [16]. 
Aggregation of surface-active agents occurs when their bulk 
concentrations reach a critical point, which is referred to as CMC. 
The dispersed nanostructures of SEDDS following dilution of lipid-
based systems are advocated to exhibit similar properties, where these 
droplets are stabilised by a thin layer of surfactants surrounding the oil 
cores (consisting dissolved drug molecules) that lowers the interfacial 
energy and induces either charge or steric effect [12]. Negative zeta 
potential values ranging from -29 to -36mV were observed for all 
SEDDS, where SEDDS with 10% CapryolTM90 (ID=C110) at drug to 
lipid ratio of 1/10 gave the most negative value and the values declined 
as drug to lipid ratios increased (Table S1). As Indapamide behaves as 
a weak monoprotic acid, it can contribute to small increment in zeta 
potential values as the amount of dissolved drug increased in SEDDS 
(5). Images from TEM showed that nanostructures in SEDDS were 
round to oval in shape after negatively stained with PTA, where the 
droplet appeared bright in contrast to the surrounding shell, which was 
darker. This observation was further confirmed by applying a positive 
stain using OST where oil cores of the droplets were very dark imparting 
higher contrast level against the shells (Figure 3) [14]. CMC values of 





C110 25 65 10 1/10
C120 25 65 10 1/20
C130 25 65 10 1/30
S130* 25 65 10 1/30
B130 30 70 0 1/30
Table 1. Formulation composition of lipid-based systems.
*substituted with Solutol®HS15
Figure 1. Solubility profiles of Indapamide in lipid-based systems and individual excipients. 
Data presented as mean and SD (n=3). Excipients composition of SEDDS can be found in 
Table 1: B1 (as in B130); C1 (as in C110, C120 or C130); S1 (as in S130)
Figure 2. Size, PDI and CMC of SEDDS.  Data presented as mean and SD (n=3).  Mean 
sizes were represented by grey bars, mean CMC values by white bars and line represented 
PDI
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Figure 3. Typical images of SEDDS from transmission electron microscopy. (a) S130 negatively stained at 40000x; (b) S130 positively stained at 30000x
SEDDS were in the range of 86-108mg/L (Figure 2), consistent with 
ranges previously reported [4]. The highest CMC was seen in SEDDS 
with the smallest drug to lipid ratio (1/10; ID=C110), which presented 
with the largest quantity of dissolved Indapamide. The lowest CMC was 
observed in SEDDS with 10% Solutol®HS15 (ID=S130) where droplet 
size of SEDDS was the smallest. When comparing the effect of lipid 
compositions, it was found that there was no significant difference of 
CMC values among SEDDS at the same drug to lipid ratio. Low CMC 
is associated to greater tendency to produce micelles for a given system. 
This may lead to a lesser risk of failure, as the system will be less prone 
to dilution effect that can result in drug precipitation [2,4]. 
Drug dissolution profiles of SEDDS alongside unprocessed powder 
and marketed tablets were presented (Figure 4). As expected, all SEDDS 
attained rapid and high drug release after exposure to the dissolution 
medium as opposed to unprocessed powder and marketed tablets where 
drug dissoluion occurred more gradually [17]. The overall drug release 
for unprocessed drug, marketed tablet and SEDDS were 47%, 91% and 
97-98%, respectively, where dissolution enhancement from SEDDS was 
significantly higher (p<0.05). Percentages drug release of SEDDS were 
maintianed over the study period, confirming that SEDDS not only 
accomplished its solubilisation effect but also showed a ‘supersaturation 
effect’ as high level of drug re-precipitation was not observed in SEDDS 
[18]. This was not only contributed to blending Labrasol with other 
surfactants [19,20] but also high drug solubility with low CMC of these 
SEDDS for preparations containing 5mg of Indapamide, which was a 
standard dose for the marketed products. 
Stability profiles of SEDDS were observed for up to 6 months under 
normal storage condition (25oC) and at high temperature (40ºC). 
The dissolution profiles of SEDDS at 3- and 6-months exhibited same 
patterns and they were not significantly different when compared to 
fresh samples when stored at 25oC (p>0.05) (Figure S2). At 40oC, 
similar pattern was observed except for SEDDS with 10% Solutol®HS15 
(ID=S130) where the overall release was reduced to 91% possibly due to 
limited re-precipitation. Thus, dissolution enhancement by SEDDS was 
not compromised for most SEDDS. When comparing size distribution 
of the stored SEDDS, they were similar to their respective fresh samples, 
for instance, SEDDS with 10% Solutol®HS15 with the smallest size and 
SEDDS without the third component gave the highest PDI regardless 
of the storage temperatures (Figures S3 &S 4). Nonetheless, stored 
samples tend to form smaller droplets without affecting PDI patterns 
(p>0.05) partly due to aging or heat exposure. Hence, the stored lipid-
based systems maintained their self-emulsifying capacity. 
Figure 4. Dissolution profiles of fresh SEDDS, unprocessed drug powder and marketed 
generic tablets using water as dissolution medium. Values were represented as mean and 
standard deviation
Conclusions
In this study, lipid-based system consisting of Labrasol, 
Labrafil®M1944CS and Capryol™90 has been considered as the 
best preparation as it can self-emulsify into SEDDS with small size 
distribution and with significantly enhanced Indapamide dissolution 
at the smallest drug to lipid ratio. Moreover, independent of drug to 
lipid ratios, the SEDDS remains stable for up to six months regardless 
of storage conditions. The dissolution enhancement was resulted from 
the ability of this lipid-based system to self-emulsify with formation 
of stable nano-sized dispersions, high drug solubility in SEDDS and 
low CMC of the dispersed system to withstand dilution by dissolution 
medium. 
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